Moderna Stock
Moderna, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Stéphane Bancel
- Employees
- 4,700
- Market cap
- $87 B
- IPO
- 07/12/2018
Moderna, Inc. (MRNA) is a specialized player in the healthcare/biotechnology sector based in Cambridge, Massachusetts. The technology company utilizes its messenger RNA (mRNA) platform to develop therapeutics and preventive medicines for infectious diseases, cancer, and rare diseases. With a market capitalization of…
AI-generated company profile based on the figures on this page, last updated on 01/10/2026. Not investment advice.
Moderna stock: price history
1D
-7.8%
1W
-3.1%
1M
+49.7%
6M
+305.8%
YTD
+639.3%
1Y
+703.3%
2Y
+279.4%
5Y
-32.8%
10Y
–
Next earnings date
Next earnings date
06/11/2026 (in 20 days)
Volatility around earnings
~8% stronger price swings than usual
Moderna stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 16/10/2026.
Business model & megatrends
Robust business model that benefits noticeably from at least one megatrend.
1 more assignment (Enabler/Second row) Pro-only.
Moderna is a biotechnology company specializing in the development and commercialization of therapies based on messenger RNA. The business model encompasses the manufacturing and sale of vaccines against various diseases such as COVID-19, influenza, and RSV, as well as approaches in cancer immunology and rare diseases. Revenue is generated primarily through product sales, supplemented by licensing fees, grants, and collaborations. The company operates globally, with a focus on the US market, and strategic alliances with prominent partners reinforce its market presence.
- Revenue model
- Transactional
- Recurring revenue
- None
- Pricing power
- Strong
- Moat
- Wide
- Moat type
- Regulatory
- Capital intensity
- High
- Customer concentration
- Unknown
Suppliers & customers in our universe
Vertex Pharmaceuticals IncorporatedDescriptionAsk the agents about Moderna
Analyst assessment of Moderna
PRICE TARGET LOW
US$25.00
CONSENSUS
US$117.40
MEDIAN
US$127.50
PRICE TARGET HIGH
US$245.00
0
STRONG BUY
8
BUY
15
HOLD
6
SELL
0
STRONG SELL
29
TOTAL · Hold
As of: 15/10/2026
Moderna stock metrics
P/E
-27.32
P/B
12.77
EV/EBITDA
-30.61
RETURN ON EQUITY
-11.6%
NET MARGIN
-539.3%
DEBT/EQUITY
0.19
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
93.2%
FLOAT SHARES
372,063,894
AVG. DAILY VOLUME (30D)
16,395,900
Insider transactions (SEC)
Hoge Stephen
Hoge Stephen
Hoge Stephen
Hoge Stephen
Hoge Stephen
Attention
16 mentions today in US forums, 23% more than yesterdayPrice since yesterday: -7.8%
Search (Google Trends)
Forums (Reddit)
See the full forum history with Pro.
Institutional holders
Comparable stocks
Frequently asked questions about Moderna stock
What does Moderna do?
Moderna, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Stéphane Bancel, the company employs around 4,700 people.
The IPO was on 07/12/2018; the stock trades on NASDAQ under the ticker MRNA.
What do analysts say about Moderna stock?
29 analysts rate the stock, the consensus is Hold (as of 15/10/2026).
The average price target is US$117.40, ranging from US$25.00 to US$245.00, with a median of US$127.50.
This is an external assessment, not a statement by Market Jury.
When does Moderna report next?
The next earnings date is 06/11/2026.
Around past earnings, price swings were roughly 8% stronger than usual.
Does Moderna pay a dividend?
No, Moderna currently does not pay a dividend.
Which stocks are comparable to Moderna?
Comparable stocks include Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences, Summit Therapeutics and Halozyme Therapeutics.
How can I get Moderna stock analyzed?
Clicking "Analyze stock" lets five strategies assess Moderna against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.